Pharmacia (Sep 2021)

Biomarkers of iron status in allopurinol-treated renal stone patients

  • Adnan A. Zainal,
  • Ibrahim M. Faisal,
  • Abdulla A. Ahmad

DOI
https://doi.org/10.3897/pharmacia.68.e70275
Journal volume & issue
Vol. 68, no. 3
pp. 633 – 642

Abstract

Read online Read online Read online

Limited evidence exists on the effect of xanthine oxidase inhibitors in nephrolithiasis patients on iron status markers, beyond their effects on urate. The aim of this study was to investigate whether allopurinol therapy was associated with a significant impact on parameters related to iron status, in patients with renal stones. Allopurinol treatment was associated with a nonsignificant decline in serum uric acid. There were no significant differences in serum levels of transferrin and ferritin after treatment with allopurinol compared to pre-treatment levels. A non-significant fall in serum levels of haptoglobin was registered. The drug was associated with a significant rise in serum iron levels. Serum uric acid and iron did not show a significant correlation with any parameter in the study. Allopurinol exerted an overall non-significant effect on iron metabolism in nephrolithiasis patients, save for serum iron, this entails lack of untoward effects in populations with-iron related conditions.